HLA-A and myeloid sarcoma: Conversely, a significantly lower EBV viral load was observed in MS patients expressing the HLA-A*02 antigen (HLA-A*02+) (N = 44/117) (2.0; 2.0–2.1 copies/μg), which is suggested to be a protective factor in MS, compared to those without the allele (HLA-A*02−) (N = 73/117) (2.9; 2.00–37.65 copies/μg; p = 0.01) (Fig. 4a).